Akorn (AKRX) : $11.6 million worth of transactions were on upticks in Akorn (AKRX), compared to $3.03 million on downticks. The ratio between the two was 3.83, whereas, the net money flow stood at a healthy $8.57 million on Mondays session. The consistent buying on upticks in the stock accounted for $8.28million worth of trades. The total money flow into the stock stood at $8.28 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.85%. The stock was trading at $30.47, with a drop of $0.26 over the previous days close. The stock recorded -1.77% for the week.
Akorn, Inc. has lost 0.75% in the last five trading days and dropped 2.28% in the last 4 weeks. Akorn, Inc. is up 9.56% in the last 3-month period. Year-to-Date the stock performance stands at -18.33%.
Akorn (NASDAQ:AKRX): The stock opened at $30.88 on Monday but the bulls could not build on the opening and the stock topped out at $31.14 for the day. The stock traded down to $30.39 during the day, due to lack of any buying support eventually closed down at $30.47 with a loss of -0.85% for the day. The stock had closed at $30.73 on the previous day. The total traded volume was 880,794 shares.
In a related news,The officer (Sr VP Gen Counsel & Secretary) of Akorn Inc, Bonaccorsi Joseph sold 6,500 shares at $29.84 on June 14, 2016. The Insider selling transaction had a total value worth of $193,960. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Akorn Inc. (Akorn), together with its wholly owned subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products. The Company specializes in sterile and non-sterile dosage forms, including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company operates in two segments: Prescription Pharmaceuticals, which is engaged in the sale of branded and generic prescription pharmaceuticals, and Consumer Health, which is engaged in the sale of branded and private label consumer and animal health products. The Company operates pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York, and Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, and an additional warehousing facility in Amityville, New York.